Scholarlink

<p>Gestational diabetes mellitus (GDM) is associated with pregnancy and marked by impaired glucose regulation, which poses significant health risks for both the mothers and their offspring. We investigate homoplantaginin as a potential therapeutic agent for managing gestational diabetes mellitus and its related complications in experimental rats. Gestational diabetes was induced in rats using STZ and treated with homoplantaginin for a period of 2 weeks. We assessed the homoplantaginin’s antidiabetic potential by monitoring body weight, fasting blood glucose (FBG), and glycemic index in GDM rats. We also evaluated protective effects of homolantaginin on organ damage, oxidative stress, and inflammatory responses in GDM rats. Histopathological analysis was conducted on the pancreas tissues collected from experimental rats. The present findings showed that homoplantaginin increased bodyweight and survival index of pups and reduced FBG in GDM rats. It also increased bodyweight and insulin levels, reduced inflammation and oxidative stress responses, and reduced GDM-induced lipid profiles, hepatic and liver comorbidities, and decreased the histological changes in the pancreatic tissues. These findings suggest that homoplantaginin was beneficial for both the mother and the fetus, improving quality of rat pups. Overall, this study confirms the safety and efficacy of homoplantaginin as a potential therapeutic agent for treating GDM in pregnant women.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the antioxidant and anti-inflammatory therapeutic potential of homoplantaginin, a flavonoid glycoside, in ameliorating gestational diabetes mellitus: in vivo study

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Huapeng Yu,
  • XueMei Yu,
  • YanHua Liu,
  • Abdullah A. Alarfaj,
  • Abdurahman Hajinur Hirad

摘要

Gestational diabetes mellitus (GDM) is associated with pregnancy and marked by impaired glucose regulation, which poses significant health risks for both the mothers and their offspring. We investigate homoplantaginin as a potential therapeutic agent for managing gestational diabetes mellitus and its related complications in experimental rats. Gestational diabetes was induced in rats using STZ and treated with homoplantaginin for a period of 2 weeks. We assessed the homoplantaginin’s antidiabetic potential by monitoring body weight, fasting blood glucose (FBG), and glycemic index in GDM rats. We also evaluated protective effects of homolantaginin on organ damage, oxidative stress, and inflammatory responses in GDM rats. Histopathological analysis was conducted on the pancreas tissues collected from experimental rats. The present findings showed that homoplantaginin increased bodyweight and survival index of pups and reduced FBG in GDM rats. It also increased bodyweight and insulin levels, reduced inflammation and oxidative stress responses, and reduced GDM-induced lipid profiles, hepatic and liver comorbidities, and decreased the histological changes in the pancreatic tissues. These findings suggest that homoplantaginin was beneficial for both the mother and the fetus, improving quality of rat pups. Overall, this study confirms the safety and efficacy of homoplantaginin as a potential therapeutic agent for treating GDM in pregnant women.